Stockreport

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Septerna, Inc.  (SEPN) 
PDF SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financia [Read more]